modelCimetidineCombinations
Extends from Pharmacolibrary.Drugs.ATC.A.A02BA51.
Information
| name: | CimetidineCombinations | |
| ATC code: | A02BA51 | route: | oral |
| compartments: | 1 | |
| dosage: | 400 | mg |
| volume of distribution: | 1.0 | L |
| clearance: | 250 | ml/min |
| other parameters in model implementation | ||
Cimetidine is a histamine H2-receptor antagonist used to reduce stomach acid production and is primarily prescribed for peptic ulcer disease, gastroesophageal reflux, and related conditions. The 'combinations' refers to formulations where cimetidine is administered together with other agents for enhanced therapeutic effect. Cimetidine is still approved and used in some regions, although newer alternatives are often preferred.
Pharmacokinetics
Pharmacokinetic parameters are estimated for healthy adult individuals for cimetidine when administered orally as part of a combination drug, based on known monotherapy data for cimetidine and standard pharmacokinetic principles. No direct publication with combination PK parameters was identified.
References
Chow, MS, et al., & Hilleman, D (1988). Propafenone: a new antiarrhythmic agent. Clinical pharmacy 7(12) 869–877. PUBMED:https://pubmed.ncbi.nlm.nih.gov/3061720
Plosker, GL, & Figgitt, DP (2004). Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. PharmacoEconomics 22(6) 389–411. DOI:10.2165/00019053-200422060-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15099124
Li, J, et al., & LoRusso, P (2014). Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics. Clinical cancer research : an official journal of the American Association for Cancer Research 20(15) 3931–3944. DOI:10.1158/1078-0432.CCR-14-0791 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24947923
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)